All hospital outpatients, emergency patients, and inpatients

Guided by the mission of "Embracing Constant Change to Fulfill an Unchanging Mission" the Department of Pathology and Laboratory Medicine at Taipei Veterans General Hospital established a smart laboratory model integrating innovation, sustainability, resilience, and patient-centered quality.

Operating Taiwan’s largest fully automated track laboratory system, it seamlessly merges specimen transport, processing, testing, verification, archiving, and monitoring. Digital integration and real-time surveillance transform conventional workflows into a highly automated, data-driven platform.

Prioritizing patient safety, the department delivers outstanding quality: 99.99985% patient ID accuracy, 99.99998% safe specimen delivery, 99.9999% report accuracy, 100% critical value notification, and 92% automated verification. Patient and physician satisfaction exceed 98%, reflecting exceptional clinical reliability.

Championing sustainability, the lab uses 100% paperless workflows and integrated testing for 77% of items, saving 176 trees, cutting 26.3 metric tons of carbon emissions yearly, and boosting per capita productivity by 37%.

During COVID-19, the department demonstrated high resilience by supporting 11 national screening missions, running 430,000+PCR tests, and establishing pathogen sequencing platforms. Moving forward, it continues advancing precision medicine via aligned NGS and molecular diagnostics, acting as a backbone for smart healthcare, public health, and personalized medicine.

• Smart Automated Laboratory: Established the nation's largest automated testing track and a cross-building specimen transport system, achieving seamless workflow integration and high efficiency.

• Smart Outpatient Phlebotomy Center: Implemented automated check-in and test tube preparation systems, combined with senior-friendly, barrier-free spaces to shorten waiting times and enhance safety.

• Innovative Pooled Testing: Pioneered the integration of a "pooled testing model" into a rapid POCT platform, maximizing screening capacity during the pandemic and demonstrating resilience in epidemic prevention.

• Precision Medicine and AI Applications: Established the Precision Medicine Testing Center, integrating Next-Generation Sequencing (NGS), digital pathology, and AI-assisted systems to support personalized treatment.

• Innovative XR Medical Laboratory Education: Pioneered the development of the "Venipuncture MR-OSCE Training Module" and the "Interactive Digital Microscopy Learning Platform," leading medical education toward smart transformation.

• ESG & Sustainability: Implemented smart tube-consolidation and 100% paperless workflows, eliminating 1.08 million test tubes and 2.92 million paper requisitions annually to achieve tangible carbon reduction outcomes.

• Processes up to 45,000 specimens daily, demonstrating the robust laboratory capacity of the medical center.

• Achieves a 99.99985% patient identification accuracy and a 99.99998% accurate specimen delivery rate, ensuring patient safety with ultimate precision.

• Maintains a 99.9999% report accuracy and a 100% real-time critical value notification rate, achieving a 98.33% physician satisfaction and strengthening clinical trust in testing services.

• Supported 11 national-level pandemic screening missions and completed over 430,000 COVID-19 tests, showcasing solid public health resilience.

• Completed 252 emerging pathogen genomic sequences with real-time uploads to international databases, enhancing critical variant surveillance capabilities.

• Promotes specimen tube consolidation and fully paperless workflows, saving millions of consumables annually and reducing carbon emissions by 39.5 metric tons.

• Processes 45,000 daily specimens with a 16.2% annual growth in service volume, demonstrating robust capacity to support medical center operations.

• Improved overall testing efficiency by 80% and reduced average ER report turnaround times to 16 minutes, effectively enhancing real-time clinical decision-making for critical care.

• Shortened HbA1c report times to 39 minutes, significantly boosting efficiency for chronic disease care and follow-up consultations.

• Achieved 99.99985% patient identification accuracy and 99.99998% safe specimen delivery, ensuring complete workflow safety with ultimate precision.

• Maintained 99.9999% report accuracy and 100% critical value notification, comprehensively solidifying clinical diagnostic reliability and healthcare quality.

• Reached a 92% automated verification rate and 100% specimen tracking, accelerating report release and strengthening anomaly traceability mechanisms.

• Increased per capita productivity by 37%, saving 1.08 million test tubes and 2.92 million paper requisitions annually, and reducing carbon emissions by 39.5 metric tons to balance operational efficiency with environmental sustainability.

• Actively supported 11 large-scale pandemic screening missions, completing over 430,000 COVID-19 tests to fully demonstrate public health emergency resilience.

• Solidified emerging pathogen sequencing capabilities by completing 252 genomic sequences, establishing a critical variant surveillance and real-time global data uploading mechanism.

• Achieved a 99.99985% patient identification accuracy, effectively eliminating the risk of patient misidentification.

• Maintained a 99.99998% accurate specimen delivery rate with a mere 0.00002% loss rate, ensuring the complete safety of end-to-end specimen tracking.

• Ensured a 99.9999% report accuracy rate and minimized the report correction rate to 0.0001%, upholding highly reliable testing quality.

• Attained a 100% critical value notification rate and optimized interception mechanisms, guaranteeing the prompt clinical management of high-risk results.

• Reached a 92% automated report verification rate and a >98% automatic instrument data transmission rate, significantly enhancing workflow efficiency and reducing manual errors.

• Optimized turnaround time (TAT) risk control, achieving a >97% completion rate for 30-minute ER reports and >98% for 40-minute outpatient reports.

• Fortified multiple defense lines against abnormal reports; alongside maintaining a strict >95% QC pass rate, an automated report auditing and comparison mechanism was introduced to ensure the safety of clinical report releases.

• Implemented a delayed notification warning system for infectious diseases, effectively improving the timeliness and regulatory compliance of statutory reporting.

• Sustained continuous CAP accreditation for over 20 years, consistently upholding the highest globally recognized quality standards.

• Overall and elderly patient satisfaction exceeds 98%, demonstrating consistent and patient-friendly service quality.

• Patient willingness to return for future visits surpasses 98%, significantly enhancing medical trust and service loyalty.

• Satisfaction with the waiting environment approaches 98%, and waiting time satisfaction exceeds 92%, reflecting highly optimized outpatient workflows.

• Outpatient phlebotomy satisfaction reached 98.4%, showcasing successful improvements in sampling procedures and elevated service quality.

• Overall physician satisfaction stands at 98.33%, firmly strengthening clinical trust in laboratory services.

• High satisfaction with report accuracy (99.57%) and report formatting (99.23%) highlights improved efficiency in clinical interpretation and diagnostic decision-making.

• Excellent ratings for reference range applicability (99.03%) and reporting timeliness (98.37%) ensure robust support for real-time and precise clinical judgments.

• Satisfaction with critical value notifications (98.03%) and test ordering convenience (>97%) bolsters high-risk patient safety and clinical operational efficiency.

• Test repertoire adequacy reached 95.63%, comprehensively supporting diverse clinical diagnostic and treatment needs.

• Maintained continuous CAP (College of American Pathologists) accreditation since 2003, ensuring testing quality and lab management align with global standards.

• Authored 24 SCI publications from 2020 to 2024, elevating research capacity and international presence in laboratory medicine.

• Executed 16 industry-academia collaborations, working with global biotech firms, pharmaceutical companies, and research institutes to advance the R&D and clinical translation of diagnostic technologies.

• Awarded one U.S. patent and one Taiwan patent, reflecting strong innovation capabilities and a well-planned intellectual property strategy.

• Establish a smart laboratory paradigm to fundamentally enhance testing efficiency, accuracy, and overall healthcare quality.

• Implement full-workflow automation to minimize manual interventions and effectively reduce specimen handling errors.

• Build end-to-end specimen tracking to strictly strengthen specimen safety and comprehensive anomaly traceability.

• Accelerate report turnaround times to robustly support real-time clinical decision-making for emergency and critical care patients.

• Ensure real-time critical value notifications to facilitate the rapid clinical management of high-risk patients.

• Develop a precision medicine platform to continuously support advanced cancer diagnostics, targeted therapies, and personalized treatment.

• Advance epidemic testing platforms to significantly strengthen the surveillance of emerging infectious diseases and public health response capabilities.

• Promote paperless workflows and consolidated testing to reduce consumable usage and actively practice green healthcare and sustainability.